Actinium Pharmaceuticals (ATNM) has shared an update.
Actinium Pharmaceuticals, Inc. has announced an upcoming regulatory filing for Iomab-B, aimed at treating relapsed or refractory acute myeloid leukemia (r/r AML). The press release, detailing this significant step toward potential market approval, emphasizes the company’s progress but also notes that the information provided will not be updated nor is it considered material under securities regulations. This move signals a key development for investors monitoring advancements in biopharmaceutical treatments for challenging conditions like r/r AML.
For an in-depth examination of ATNM stock, go to TipRanks’ Stock Analysis page.
